Table 3. Longer-term outcomes in non-transitioned cases in a sample of young people at ultrahigh risk for psychosis.

Outcome	All Non-transitioned (N=49)		Omega-3 group (N=30)		Placebo group (N=19)
	N	%	N	%	N	%
Attenuated psychosis	11	22.4	8	26.7	3	15.8
Functioning*
Good functioning	24	49.0	14	46.7	10	52.6
Mild or moderate impairment	21	42.4	14	46.7	7	36.8
Severe impairment	4	8.2	2	6.7	2	10.5
Employment
Full-time	33	67.3	21	70.0	12	63.2
Part-time	3	6.1	1	3.3	2	10.5
Unemployed	13	26.5	8	26.7	5	26.3
Non-psychotic disorder
Any disorder	27	55.1	14	46.7	13	68.4
Mood disorder	18	36.7	12	40.0	6	31.6
Anxiety disorder	13	26.5	8	26.7	5	26.3
Substance use disorders	5	10.2	2	6.7	3	15.8
Other disorder†	1	2.0	0	0.0	1	5.3
Psychiatric treatment‡
Outpatient psychiatric care	30	61.2	17	56.7	13	68.4
Inpatient psychiatric care	10	20.4	5	16.7	5	16.7
Supplementation§	2	4.1	2	6.7	0	0.0

^*Good functioning GAF score >70; Mild or moderate impairment GAF score between 51 and 70; severe impairment GAF score ≤50.

^†Somatization disorder.

^‡Service use during the follow-up period.

^§Supplementation with omega-3 PUFAs >1 month.